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Abstract
Pneumonia is considered to be one of the leading causes of death worldwide. The outcome
depends on both, proper antibiotic treatment and the effectivity of the immune response of
the host. However, due to the complexity of the immunologic cascade initiated during infec-
tion, the latter cannot be predicted easily. We construct a biomathematical model of the
murine immune response during infection with pneumococcus aiming at predicting the out-
come of antibiotic treatment. The model consists of a number of non-linear ordinary differen-
tial equations describing dynamics of pneumococcal population, the inflammatory cytokine
IL-6, neutrophils and macrophages fighting the infection and destruction of alveolar tissue
due to pneumococcus. Equations were derived by translating known biological mecha-
nisms and assuming certain response kinetics. Antibiotic therapy is modelled by a transient
depletion of bacteria. Unknown model parameters were determined by fitting the predictions
of the model to data sets derived from mice experiments of pneumococcal lung infection
with and without antibiotic treatment. Time series of pneumococcal population, debris, neu-
trophils, activated epithelial cells, macrophages, monocytes and IL-6 serum concentrations
were available for this purpose. The antibiotics Ampicillin and Moxifloxacin were consid-
ered. Parameter fittings resulted in a good agreement of model and data for all experimental
scenarios. Identifiability of parameters is also estimated. The model can be used to predict
the performance of alternative schedules of antibiotic treatment. We conclude that we
established a biomathematical model of pneumococcal lung infection in mice allowing pre-
dictions regarding the outcome of different schedules of antibiotic treatment. We aim at
translating the model to the human situation in the near future.
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Introduction
Pneumonia is a high incidence infectious disease and a major cost driver in health care systems.
It is one of the leading causes of death worldwide, especially within childhood [1]. Starting as
pathogen-driven local inflammation in the lung it might become systemic after destruction of
the alveolar-endothelial barrier. This often results in life-threatening organ involvement and
sepsis [2, 3].
The outcome of pneumonia infection depends on both, proper antibiotic treatment and the
effectivity of the immune response of the host. However, predicting the outcome is a difficult
task due to the complexity of the immunologic cascade initiated during infection. Moreover it
depends on the pathogen, kind, dosing and timing of antibiotic treatment and individual risk
factors [3].
Here, we construct a biomathematical model of murine immune response during pneumo-
nia aiming at predicting the outcome of antibiotic treatment. Focussing on inbred mice data
after infection with streptococcus pneumoniae allows us to neglect the impact of different path-
ogens and a variety of individual parameters influencing outcome of therapies in humans.
Our model consists of a number of non-linear ordinary differential equations describing
lung dynamics of pneumococcal population, the inflammatory cytokine IL-6, neutrophils and
macrophages fighting the infection and destruction of alveolar tissue due to pneumococcus.
Equations were derived by adapting a lung infection model recently proposed by Smith et al.
[4]. Corresponding equations are based on the translation of known biological mechanisms of
the assumed cascade of immune defence mechanisms consisting of alveolar macrophages fight-
ing the infection first, migrating neutrophils from blood, and finally, migrating monocytes
which differentiate to macrophages as the last line of defense [5].
Here, we aim at parametrizing the model on the basis of available mouse data. This requires
some adaptations of model equations as well as representation of model compartments by
measured biological quantities. Moreover, we included the effects of antibiotic treatment in the
equations to explain data during treatment with either Ampicillin or Moxifloxacin.
We study the qualitative behaviour of the model, estimate parameters and discuss their sen-
sitivity in detail. We show how it can be used to predict the outcome of yet untested options of
antibiotic therapy demonstrating a way to validate the model on the basis of biologically test-
able hypotheses.
Methods
General Structure of the Model
We adapted an ordinary differential equation model from Smith et al. [4]. The original model
describes the dynamics of pneumococci, neutrophils and monocytes differentiating to macro-
phages in lung-infected mice. The system is assumed to be regulated by a cytokine response
which was modelled phenomenologically. Destruction of the epithelial barrier is also modelled.
Here, we aim at parametrizing the model on the basis of experimental mice data of pneumo-
coccus lung infection treated with two antibiotic drugs, namely Moxifloxacin or Ampicillin.
This requires some model adaptations including additional compartments and assumptions.
We present our model assumptions and equations in the following. A schematic structure of
the model is sketched in Fig 1.
Model equations and assumptions
Compartment P: pneumococci. For the bacterial population in the lung alveoli, we
assume a logistic growth with rate kP until saturation Pmax is achieved. The initial value is zero.
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We always start the simulation with an infectious event. This is modelled by the inhalation
function:
PneuStart ¼
XN
i¼1
doseiPneu
tPneu
Hvðt  ~tiÞ Hvðt  ~ti  tPneuÞð Þ ð1Þ
where Hv is the Heaviside-function Hv ¼ 0 : x < 0
1 : x  0
(
, and ~ti are the time points at which
bacteria at dose doseiPneu are inhalated. Here, we only consider an initial single infectious event,
i.e. ~ti ¼ 0;N ¼ 1. The inhalation function is multiplied by the factor InfFactor = 0.001. This
factor translates applied amount of bacteria to those in 1μl broncho-alveolar lung ﬂuid (BALF)
after 24 hours. The number of bacteria that actually settles per volume after inhalation of a
ﬁxed bacteria dose cannot be determined since no data are available directly after infection (see
section data).
Bacteria were eliminated by macrophages and neutrophils. This is modeled by a reaction
kinetic where the pneumococcus part is saturated by a Michaelis-Menten kinetic representing
the limited killing capacity of an immune cell. This is in contrast to Smith et al. where an unsat-
urated kinetic was assumed for both, neutrophil and macrophage elimination. Summarizing
Fig 1. Structure of the model. Compartments: pneumococcal population (P), IL-6, debris (D), unaffected
epithelial cells (EU), epithelial cells with pneumococci attached to cell surface receptors (EA) and
macrophages/neutrophils (M, N).
doi:10.1371/journal.pone.0156047.g001
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our considerations result in the following equation.
dP
dt
¼ InfFactor  PneuStart þ kP  PðtÞ  1
PðtÞ
Pmax
 
kPN  NðtÞ 
PðtÞ
nþ PðtÞ  kPM MðtÞ 
PðtÞ
nþ PðtÞ
ð2Þ
We will later add the effect of antibiotic treatment to this equation.
Compartment EU: unaffected epithelial/endothelial cells. The barrier between the lung
and the circulation is formed by epithelial and endothelial cells (endoepithelial barrier). Here,
we do not distinguish between epithelial and endothelial cells and refer to epithelial cells in the
following according to Smith et al. A major disease mechanism of pneumococci is the destruc-
tion of this barrier increasing the permeability of the barrier eventually resulting in a systemic
infection. Therefore, we model the compartment of unaffected epithelial cells in the following
way.
In the absence of pneumococci, the epithelium is in steady-state. During infection, epithelial
cells transform to affected epithelial cells according to an unsaturated reaction kinetic of first
order with rate parameter kEUP. Thus
dEUðtÞ
dt
¼ kEU  1
EUðtÞ
EU0
 
 kEUP  PðtÞ  EUðtÞ ð3Þ
i.e. in contrast to Smith et al. [4], our equations return to steady state after elimination of pneu-
mococci [6].
Compartment EA: affected epithelial cells. The compartment EA describes epithelial
cells affected by pneumococci. The influx of this compartment equals the second term of Eq
(3). We assume that the cells are destroyed in a first order kinetic transforming the cells into
debris. A constant rate dE is assumed for this process.
dEAðtÞ
dt
¼ kEA  PðtÞ  EUðtÞ  dE  EAðtÞ ð4Þ
Since epithelial cells under attack produce pro-inﬂammatory cytokines [7], we assume that EA
regulates the cytokine production considered in the next equation.
Compartment C: cytokine IL-6. In analogy to [4], cytokines were produced by affected
epithelial cells and by macrophages. While in [4] the compartment C addresses the cytokines
TNF-α and IL-1, we consider it as a representative of IL-6 available in our data. We assume a
production by affected epithelial cells at rate kCEA and by macrophages at rate kCMA. Further,
we assume a constant baseline production PC. In steady state there is a cytokine level of C0.
dCðtÞ
dt
¼ kCEA  EAðtÞ þ kCMA MðtÞ  PðtÞ  dC  CðtÞ þ PC ð5Þ
with the (implicit) steady state condition
PC ¼ dC  C0 ð6Þ
Compartment N: neutrophils. Neutrophils were assumed to be positively correlated with
the cytokine IL-6 with factor kNC, limited by the maximum number Nmax [4, 8]. In analogy to
[4], they were reduced by bacteria at rate dNP or by natural cell death at rate dN. In steady state
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we assume a neutrophil count of N0, realised by a baseline recruitment PN.
dNðtÞ
dt
¼ kNC  CðtÞ  1
NðtÞ
Nmax
 
dNP  NðtÞ  PðtÞ  dN  NðtÞ þ PN
ð7Þ
where
PN ¼ dN  N0  kNC  C0  1
N0
Nmax
 
ð8Þ
Compartment D: debris. In analogy to [4], apoptotic neutrophils, eliminated bacteria and
affected epithelial cells contribute to the increase of debris at rates kDN, kDNP and kDEA. Debris
is cleared by macrophages at rate kMAD, and by other processes with rate dD. In the data avail-
able for our modelling [9], debris is measured in terms of a semi-quantitative histological
score. Therefore, we adapted the parameters accordingly.
dDðtÞ
dt
¼ kDNP  NðtÞ  PðtÞ þ kDN  NðtÞ þ kDEA  EAðtÞ
kMAD MðtÞ  DðtÞ  dD  DðtÞ
ð9Þ
with
dD ¼
kDN  N0  kMAD M0  D0
D0
ð10Þ
In contrast to [4], D0 is set to 1, because the sham+solvent group data from [9] showed a mean
score of 1.
Compartment M: macrophages. In steady state, there is a pool of alveolar macrophages
fighting the infection first [5]. Additionally, monocyte to macrophage differentiation was pro-
moted by IL-6 [10]. In our model, we do not distinguish between alveolar macrophages and
migrated monocyte derived macrophages.
dMðtÞ
dt
¼ kMAC  kM  CðtÞ
CðtÞ þ kM
 dM MðtÞ þ PM ð11Þ
with steady state condition
PM ¼ dM M0 
kMAC  kM  C0
C0 þ kM
ð12Þ
Modelling antibiotic treatment
To describe the effect of antibiotic therapy, we developed an injection function for the different
antibiotic drugs. The antibiotics injection function ABIOinj(t) can be written as a sum of pulse
functions
ABIOinjðtÞ ¼ doseABIO  kABIO
tABIO

XN
i¼1 Hvðt  ~tiÞ Hvðt  ~ti  tABIOÞð Þ ð13Þ
where ABIO 2 {Amp, Mox}, and ~ti are the time points at which antibiotics at dose doseABIO
were administered. In [9], 0.02 mg/g Ampicillin or 0.1 mg/g Moxiﬂoxacin were applied. kAmp
and kMox are ampliﬁcation factors describing the antibiotic effect of the speciﬁc drugs. The
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duration of injection (tABIO) is set to 0.1 hour. The applied dose is normalised to this injection
time by the factor 1/tABIO.
Modelling pharmacokinetics of antibiotics
We assume that antibiotic treatment acts with some time delay modelled by two delay com-
partments, where CðiÞABIOðtÞ is the concentration of the antibiotic drug in the compartment i:
dCðiÞABIOðtÞ
dt
¼ Cði1ÞABIO outðtÞ  kDelayABIO  CðiÞABIOðtÞ i ¼ 1; 2 ð14Þ
with the settings
Cð0ÞABIO outðtÞ ¼ ABIOinjðtÞ
and
CðiÞABIO outðtÞ ¼ kDelayABIO  CðiÞABIOðtÞ i ¼ 1; 2
Cð2ÞABIO outðtÞ enters the compartment of antibiotic effect on pneumococci:
dAðtÞ
dt
¼ Cð2ÞABIO outðtÞ  dABIO  AðtÞ ð15Þ
where A(t) corresponds to the antibiotic effect and dABIO is the elimination rate. The antibiotic
effect A(t) of repetitive Moxiﬂoxacin (0.1mg/g) and Ampicillin (0.02mg/g) applications is illus-
trated in Fig 2. Adding antibiotic therapy, Eq (2) extends to
dP
dt
¼ InfFactor  PneuStart þ kP  PðtÞ  1
PðtÞ
Pmax
 
kPN  NðtÞ 
PðtÞ
nþ PðtÞ  kPM MðtÞ 
PðtÞ
nþ PðtÞ  AðtÞ  PðtÞ
ð16Þ
Numerical Methods for Simulation
Simulations were performed with MATLAB 7.5.0.342 (R2007b) using the SIMULINK
toolbox (The MathWorks Inc., Natick, MA, USA). Numerical solutions of the equation system
are obtained using the variable step solver from Adams and Bashford (ode113, SIMULINK
toolbox).
Data
For our model, we used the data published in [9], which were originally collected for compar-
ing the anti-inflammatory effect of Moxifloxacin and Ampicillin. Data comprise time series of
pneumococci (measured as colony-forming units), neutrophils, and macrophages in BALF (no
differentiation between alveolar macrophages and those derived from immigrated monocytes
possible), IL-6 measured in BALF, debris assessed by a histological score of the lung tissue and
permeability (measured by the ratio of BALF and murine serum albumine).
Murine pneumonia. Animal experiments were approved by institutional and governmen-
tal (LaGeSo Berlin) authorities and performed according to the Helsinki convention for the use
and care of animals.
A Biomathematical Model of Pneumococcal Lung Infection and Antibiotic Treatment in Mice
PLOS ONE | DOI:10.1371/journal.pone.0156047 May 19, 2016 6 / 22
Female C57Bl/N mice (8–10 weeks old) were anaesthetized by i.p. ketamine (1.6 mg) and
xylazine (0.5 mg). Next, mice were transnasally inoculated with 5  106 cfu S. pneumoniae sero-
type 3 (strain PN36, NCTC7978) in 20 μl PBS. At the respective experimental endpoints, ani-
mals were deeply anaesthetized, subjected to mechanical ventilation after tracheotomy and
exsanguinated by puncture of the vena cava inferior following median laparotomy.
Leukocyte differentiation in bronchoalveolar lavage fluid and blood. Lungs were
flushed blood free via the pulmonary artery and lavaged two times with 800 μl PBS each. Leu-
kocytes were isolated from bronchoalveolar lavage fluid (BALF) by centrifugation, pooled,
counted and differentiated by flow cytometry (FacsCalibur, BD, Heidelberg, Germany)
Fig 2. Antibiotic therapy. The resulting antibiotic effect function A(t) of Ampicillin (0.02mg/g) and Moxifloxacin (0.1 mg/g) is shown. Antibiotics were given
every 12 hours, starting 24 hours after infection.
doi:10.1371/journal.pone.0156047.g002
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according to their forward and side scatter properties, and by CD45, F4/80, Gr-1 staining (BD,
Heidelberg, Germany).
Leukocytes were quantified from whole blood using Trucount tubes and differentiated by
forward and side scatter properties, and by their CD45, Gr-1 staining properties (BD, Heidel-
berg, Germany).
Cytokine Multiplex Assays. Cytokines were measured in BALF and blood plasma by mul-
tiplex assay technique according to the manufacturer’s instructions (Bio-Rad, Hercules, CA,
USA)
To compare model and data, we used the following analogies of measured features and
modeled compartments (see Table 1).
Steady state values forN,M and EA are calculated by the geometric means of the sham+solvent
group at time points t1 = 72, t2 = 120. We use the mean of the time point 120 as the steady state
value of IL-6. The median and minimum values of lung infection score equals 1 at all timepoints,
therefore we setD0 = 1 (see Table 2).
Estimation of Parameters
To determine optimal parameter settings, we used a pointwise optimisation function for fitting
model predictions to the data. Let (ti, xi), (i = 1, . . ., N) be the time points ti with corresponding
normalised measurements xi and let f(t; k) the solution of the differential equation system. We
solve the extremal value problem
Xn
i¼1
jxi  f ðti; kÞj ! minimise with respect to k ð17Þ
The left hand side is refered to as the ﬁtness function. At this, ﬁtness functions of different
Table 1. Data and correspondingmodel compartments.
measured quantity explanation model compartment
CFU pneumococci in BALF P (pneumococci)
IL-6 IL-6 measured in BALF C (cytokine)
Lung infection histological score of epithelial D (debris)
score damage, semi-quantitative
PMN neutrophils in BALF N (neutrophils)
AM macrophages in BALF M (macrophages)
Permeability proxied by ratio BALF/serum albumine EA (affected epithelial cells)
doi:10.1371/journal.pone.0156047.t001
Table 2. Initial values.
parameter meaning value
P0 initial value of bacteria 0.00E+00 set
EU0 initial value of epithelial cells 1.00E+02 set
EUnor normal value of epithelial cells 1.00E+02 set
EA0 initial value of activated epithelial cells 0.00E+00 set
C0 initial value of IL-6 3.90E-01 set
D0 initial value of debris 1.00E+00 set
M0 initial number of macrophages 3.61E+04 set
N0 initial number of neutrophils 2.09E+02 set
doi:10.1371/journal.pone.0156047.t002
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scenarios were added. To ﬁnd optimal parameter settings, evolutionary algorithms with self-
adapting mutation step size were used [11, 12]. These are non-deterministic optimisation algo-
rithms based on mutation, realisation and survival of the ﬁttest.
To our experiences, in order to fit differential equations-based models to data, evolutionary
strategies outperform for example gradient methods since fewer computationally expensive
evaluations of the fitness function are required. Moreover, there is a higher chance that a global
optimum is found. Finally, it has been estimated that evolutionary strategies achieve the opti-
mummore quickly especially if the number of parameters is high [11], p.126, figure 31. We
successfully fitted a number of highly complex, multi-parametric models applying evolutionary
strategies (see [13–18]).
Here, we used an evolutionary strategy with one parent having three children in each gener-
ation (see [11, 12] for further details). A list of the estimated parameters can be found in
Table 3.
Results
Qualitative model behaviour
At first, we study the qualitative behaviour of our differential equation system. It can be shown
that the initial condition P = P0, N = N0,M =M0, C = C0, EA = EA0, EU = EU0, D = D0 repre-
sents a stable steady-state of the equations, i.e. the system returns to it after cure.
Proof. Compartment D is not coupled, and consequently, has no impact on stability. Con-
sidering the following order of state variables: P, EU, EA, C, N,M, the Jacobian of the system at
the steady state reads as follows:
J ¼
kP  kPN N0þkPMM0n 0 0 0 0 0
kEUP  EU0  kEUEU0 0 0 0 0
kEA  EU0 0 dE 0 0 0
kCMA M0 0 kCEA dC 0 0
dNP  N0 0 0 kNC  1 N0Nmax
 
 kNC C0
Nmax
 dN 0
0 0 0
kMACk2M
ðkMþC0Þ2
0 dM
0
BBBBBBBBBBBBBBBBB@
1
CCCCCCCCCCCCCCCCCA
Thus, eigenvalues of J are kP  kPNN0þkPMM0n ¼ 1:6201, kEUEU0 ¼ 9:3868  10
4, −dE = −0.0152,
−dC = −200.8505, kNC C0Nmax  dN ¼ 2:4770, and −dM = −0.5934. Since all eigenvalues are
strictly negative, the steady-state is locally asymptotically stable.
Depending on the initial bacterial load, simulation shows different results: As a major
requirement for biological plausibility, lower initial doses of pneumococci were successfully
removed by the immune system. However, initial bacterial load above 2.5  105 results in a dis-
seminated infection (see Fig 3).
Dropping the debris variable which is continuously increasing during this process (eventu-
ally resulting in the death of animals), the limit represents another locally stable steady-state
with respect to the other state variables. Numerically obtained values for this steady-state and
corresponding stability analysis can be found in the supplement (see S1 Appendix).
Fig 4A shows the growth of pneumococci and their elimination by neutrophils and macro-
phages. We calculate the total amount of bacteria growing over a period of 120 hours per μl of
A Biomathematical Model of Pneumococcal Lung Infection and Antibiotic Treatment in Mice
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BALF, and the total amount of bacteria eliminated by neutrophils respectively by macrophages
over this period. Low numbers of bacteria were eliminated successfully by existing (alveolar)
macrophages, while a higher starting dose needs the commitment of neutrophils. For suffi-
ciently high initial doses, the bacteria can not be controlled by the immune system. Fig 4B
shows the percental contribution of neutrophils and macrophages to elimination of bacteria
for different initial doses. For macrophages it is 100% for low doses. Neutrophils contribute
only at sufficiently high doses. This is in agreement with the biological understanding of the
process.
Table 3. Parameter values of the model.
parameter meaning value
kP pneumococcal population growth rate 7.90E-01 ﬁtted
Pmax maximal number of bacterials 7.50E+03 ﬁtted
kPN bacterial clearance by neutrophils 5.98E-04 ﬁtted
kPM bacterial clearance by macrophages 6.67E-03 ﬁtted
kEU epithelial cells growth rate 9.39E-02 ﬁtted
kEUP bacterial attachment to epithelial cells 4.33E-07 ﬁtted
kEA epitelial cells activation rate 6.79E-07 ﬁtted
dE epithelial cell degradation rate 1.52E-02 ﬁtted
kCEA cytokine production by epithelial cells 3.13E+03 ﬁtted
kCMA cytokine production by macrophages 1.09E-04 ﬁtted
Nmax maximal number of neutrophils 1.80E+06 set
kNC neutrophil recruitment rate 1.33E+03 ﬁtted
dNP bacterial-induced neutrophil death rate 1.05E-09 ﬁtted
kDNP debris from bacterial-induced neutrophil death 4.26E-12 ﬁtted
kDN debris from neutrophil death 2.42E-08 ﬁtted
kDEA debris from epithelial cell death 3.81E-04 ﬁtted
dD debris degradation rate 4.62E-06 ﬁtted
kMAD removal of debris by macrophages 1.21E-11 ﬁtted
kMAC macrophage recruitment rate by IL-6 6.33E+02 ﬁtted
dM macrophage degradation rate 5.93E-01 ﬁtted
n maximum number of bacteria per M, N 1.00E+02 set
dC IL-6 clearance rate 2.01E+02 ﬁtted
dN neutrophil degradation rate 2.48E+00 ﬁtted
kM constant 8.30E+01 ﬁtted
PN neutrophile production 5.18E-05 set
PC cytokine production 7.83E+01 set
PM macrophage production 2.12E+04 set
tPneu inhalation time 1.67E-02 set
InfFactor rate of bacterials colonizing after inhalation 1.00E-03 set
tABIO injection time for antibioticum 1.00E-01 set
kAmp antibiotic effect factor of Ampicillin 2.00E+03 ﬁtted
kMox antibiotic effect factor of Moxiﬂoxacin 6.00E+02 ﬁtted
kDelayAmp delay of antibiotic effect 9.00E-02 ﬁtted
kDelayMox delay of antibiotic effect 9.76E-02 ﬁtted
dAmp clearance of antibioticum 7.00E+00 ﬁtted
dMox clearance of antibioticum 7.00E+00 ﬁtted
doi:10.1371/journal.pone.0156047.t003
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Parameter sensitivity
We performed an extensive sensitivity analysis in order to determine the identifiability of all
model parameters. This is achieved by estimating the deterioration in fitness after changing the
parameters by +/- 2.5% (see Fig 5). The parameters maximum amount of pneumococci (Pmax),
pneumococcal population growth rate (kP), bacterial clearance by macrophages (kPM), the
recruitment rates of macrophages and neutrophils (kMAC, kNC) and the degradation rates of
macrophages and neutrophils (dM, dN) are most sensitive.
Comparison: model and data
Parameter estimates resulted in a good agreement of model and data for the available scenarios.
In Fig 6, the simulated time courses of pneumococcal population, neutrophils, IL-6, debris, EU,
Fig 3. Modelling different initial doses of pneumococci without treatment. Time series of pneumococcal population, neutrophils, IL-6,
debris, EA and macrophages in BALF are presented. The solid black curves represent simulation results with an initial bacterial load of 2.5  105,
the dashed lines with 2.4  105. As one can see, the smaller initial dose is successfully removed by the immune system, while larger doses result
in disseminated infection.
doi:10.1371/journal.pone.0156047.g003
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EA and macrophages in BALF after infection with 5  106 bacteria without treatment are pre-
sented and compared with corresponding data from [9]. For untreated mice, simulation shows
that bacteria remain on an almost constant level for more than 48 hours. This is in rough agree-
ment with the data. The apparent drop of bacteria at 36 hours is not statistically significant
(p = 0.26, Kruskal-Wallis test).
Figs 7 and 8 show comparisons of model simulations and data from infections with 5  106
Streptococcus pneumoniae treated with either 0.02 mg/g Ampicillin or 0.1 mg/g Moxifloxacin
Fig 4. Bacterial growth and elimination by the immune system.We simulated different initial dosages of bacteria without antibiotic
treatment. A: In dependance on the inhalated dose (x axis), we calculate the total amount of bacteria produced over a period of 120 hours per μl
of BALF (blue line), the total amount of bacteria eliminated by neutrophils over this period (black dashed line), and the total amount of bacteria
eliminated by macrophages over the same period (black solid line). The green dashed line represents the sum of bacteria eliminated by
neutrophils and macrophages over the period. As one can see, immune system is unable to remove all bacteria if the initial dose exceeds about
2.5  105. B: In dependance on the initial dose, the percentage of bacteria eliminated by neutrophils respectively macrophages over a period of
120 hours is depicted. After infection with lower doses, 100% of bacteria were eliminated by macrophages (solid line) over a period of 120 hours.
For higher doses, neutrophils are also involved (dashed line).
doi:10.1371/journal.pone.0156047.g004
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(data taken from [9]). The antibiotic therapies started 24 hours after infection, and the antibiot-
ics were given every 12 hours. However, according to our model results, bacteria are eradicated
already at 72 hours while numbers of immune cells are still higher than in steady-state.
Prediction
After calibration, the model can be used to predict new therapy schedules. We simulated an
infection with 5  106 bacteria and Moxifloxacin treatment every 12 hours starting 24 hours
after infection with lower dosage (0.01 mg/g) in comparison to [9]. While with a dose of 0.1
Fig 5. Sensitivity of model parameters. Single parameter values were changed by ±2.5% while the other
parameters were kept constant. Corresponding percental deterioration of the fitness function Eq (17) was
evaluated as a measure of sensitivity of the considered parameter. Longer bars correspond to more sensitive
parameters, i.e. better identifiability.
doi:10.1371/journal.pone.0156047.g005
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mg/g the bacteria can be eliminated quickly, the therapy with 0.01 mg/g Moxifloxacin is unsuc-
cessful (see Fig 9).
Next, we study different time schedules with the same dosage. In Fig 10, we simulate 0.02
mg/g Ampicillin treatment every 12 hours and every 48 hours, starting 24 hours after infection.
While the denser treatment can eliminate the bacteria, the 48 hours schedule is insufficient.
Fig 10 also shows simulations of 0.1 mg/g Moxifoxacin treatment every 12 hours and every
48 hours, starting 24 hours after infection. The denser treatment eliminates the bacteria faster
than the 48 hours schedule, but still, both therapy schedules are predicted to result in cure.
In Fig 11, another scenario is modelled. Here we gradually reduced the dose of Ampicillin
treatment during the course of the therapy. In more detail, therapy starts at t1 = 24 hours after
infection with the standard 0.02 mg/g. Dose is reduced to 0.01 mg/g at 36 hours and 48 hours.
Fig 6. Modelling infection without treatment.We compare results of model simulation with data from [9] without antibiotic treatment. Time
series of pneumococcal population, neutrophils, IL-6, debris, EU, EA and macrophages in BALF are displayed. Solid black curve represents
simulation results. Circles represent data points. The green dashed lines represent minimal and maximal observed values.
doi:10.1371/journal.pone.0156047.g006
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At 60 hours, about 2000 CFU/μl are left. Stopping treatment here results in relapse, while an
additional treatment with 0.01 mg/g results in cure. However, elimination of bacteria takes
considerably longer compared to standard therapy, where 0.02 mg/g Ampicillin is given every
12 hours until 108 hours after infection.
Discussion
In the present paper, we propose a biomathematical model of systemic lung infection in mice
caused by streptococcus pneumoniae. The model is based on differential equations of the
dynamics of pneumococci in the lung, immune cell response, inflammatory cytokines repre-
sented by IL-6 and epithelial barrier damage. We also include antibiotic treatment of the
Fig 7. Ampicillin treatment.We compare results of model simulation with data from [9] under Ampicillin treatment. Therapy starts 24 hours after
infection and is continued every 12h. Time series of pneumococcal population, neutrophils, IL-6, debris, EU, EA and macrophages in BALF are
displayed. Solid black curve represents simulation results. Circles represent data points. The green dashed lines represent minimal and maximal
observed values.
doi:10.1371/journal.pone.0156047.g007
A Biomathematical Model of Pneumococcal Lung Infection and Antibiotic Treatment in Mice
PLOS ONE | DOI:10.1371/journal.pone.0156047 May 19, 2016 15 / 22
disease incorporating the two antibiotic drugs Ampicillin and Moxifloxacin for the first time.
The system is parametrized on the basis of mice experimental data. It is our intention to keep
the model as simple as possible in order to keep a balance between biological complexity of the
immune response and the identifiability of parameters on the basis of the limited amount of
available experimental data. We obtained a good agreement of model and data showing that
our simple assumptions regarding action of antibiotic treatments are sufficient to explain the
data. After establishing the model, we demonstrate how it can be used to make relevant and
testable predictions regarding new therapy options opening a way to validate the model. We
predict for example that cure can be achieved with lower doses of antibiotics as those applied
in the current setting. However, further refinements of the model are required to incorporate
Fig 8. Moxifloxacin treatment.We compare results of model simulation with data from [9] under Moxifloxacin treatment. Therapy starts 24
hours after infection and is continued every 12h. Time series of pneumococcal population, neutrophils, IL-6, debris, EU, EA and macrophages in
BALF are displayed. Solid black curve represents simulation results. Circles represent data points. The green dashed lines represent minimal
and maximal observed values.
doi:10.1371/journal.pone.0156047.g008
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more complex regulatory mechanisms of immune response, and especially, to address the early
phase of infection.
There is a large amount of literature regarding different modelling aspects of the immune
system during lung infection. Proposed models can be categorized by the pathogen responsible
for the lung infection. For example a number of models have been proposed to describe
immune dynamics during viral infection by e.g. influenza A (see [19] for an overview of mod-
els). Models of fungal infection by Aspergillus fumigatus have been proposed by Pollmächer
and Figge [20, 21]. Here we focus on infections with streptococcus pneumoniae. Again some
models were already proposed for this situation. Guo et al. [22] presented a simple model of
pneumonia under immuno-suppression. The model of Mochau et al. [23] included some more
Fig 9. Prediction: Moxifloxacin treatment. Treatment with different doses of Moxifloxacin after infection with 5  106 Streptococcus
pneumoniae are simulated. Moxifloxacin is given every 12 hours starting 24 hours after infection. Time series of pneumococcal population,
neutrophils, IL-6, debris, EU, EA and macrophages in BALF are presented. Solid red curves represent the predicted time course with lower
dosed Moxifloxacin (0.01 mg/g). The black dashed line represents the simulation results of the higher dose (0.1 mg/g). Circles represent time
points of antibiotic treatment.
doi:10.1371/journal.pone.0156047.g009
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features, namely neutrophil response and transitions of pneumococci between lung and circu-
lating blood. Smith et al. [4] proposed an elaborated model considering alveolar macrophages,
immigrated neutrophils and immigrated monocytes differentiating to macrophages as three
important lines of immune cell response. The model also considers affection of the endothelial
barrier. Shreshta et al. [24] combined this model with a model of influenza infection in order to
study their interaction.
Our model mainly relies on the work of Smith et al. [4]. However, a number of adaptations
were necessary to obtain the desired model behaviour and to explain our data of lung infection.
Fig 10. Prediction: Different schedules of antibiotic treatment. Treatment with different schedules of Ampicillin or Moxifloxacin after infection with 5  106
Streptococcus pneumoniae are simulated. Time series of pneumococcal population, neutrophils, IL-6, debris, EU, EA and macrophages in BALF are
presented. Ampicillin 0.02 mg/g is given every 12 hours starting 24 hours after infection (dashed blue line) or every 48 hours starting 24 hours after infection
(red line). Moxifloxacin 0.1 mg/g is given every 12 hours starting 24 hours after infection (dashed black line) or every 48 hours starting 24 hours after infection
(green line).
doi:10.1371/journal.pone.0156047.g010
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Moreover, we included the effect of antibiotic treatment which was not considered in Smith
et al. In more detail, we do not distinguish between alveolar macrophages and monocyte
derived macrophages when modelling macrophage induced killing of pneumococci. We also
assumed a saturated kill kinetic of pneumococci in contrast to Smith et al. For the unaffected
endothelial cells, we assumed a production term which has the advantage that the system
returns to steady-state after successfully fighting the infection. While the neutrophil and the
debris compartment are modelled in analogy to Smith et al., we modified the equation of
Fig 11. Prediction: Dose reduction in antibiotic treatment. Treatment with modified Ampicillin schedule after infection with 5  106 Streptococcus
pneumoniae are simulated. Time series of pneumococcal population, neutrophils, IL-6, debris, EU, EA and macrophages in BALF are presented. Therapy
starts at 24 h after infection with 0.02 mg/g. Then, dose is reduced to 0.01 mg/g given every 12 hours. Ampicillin treatment is stopped after 48 h (red line) or
60 h (green line). The black dashed line shows the standard treatment with Ampicillin 0.02 mg/g every 12 hours, stopped after 108 hours.
doi:10.1371/journal.pone.0156047.g011
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macrophages. The delay term proposed by Smith was dropped and an initial condition differ-
ent from zero was chosen representing alveolar macrophages. In summary, our adaptations did
not increase the complexity of the model. Antibiotic treatment was added to the model assum-
ing a two-compartment injection model and a kill term proportional to the product of the
number of pneumococci and the drug concentration. In summary, it turned out that the
assumptions made by Smith et al. regarding major players and mechanisms of the interactions
of disease and immune system proved to be reasonable to explain our data. Only a few adapta-
tions were necessary regarding the concrete realization of equations.
We showed that our model has a number of properties desirable for biological plausibility.
At first, we proved that the system has a unique and stable pneumonia-free steady state. More-
over, we showed that there is a bifurcation regarding the initial number of pneumococci result-
ing in either cure or disseminated disease. Finally, derived model parameters suggest that the
(alveolar) macrophages are responsible for early elimination of the disease.
Parameters of our model were either kept constant (e.g. values proposed by Smith et al.) or
were estimated by fitting the predictions of the model to available experimental data. Experimen-
tal data comprised time-series of measurements in infected mice with or without antibiotic treat-
ment [9]. Experimental readouts were mapped to appropriate model compartments. However,
for some model compartments only proxy measurements are available. As example, endothelial
permeability was estimated by the ratio of BALF and murine serum albumin and was mapped to
the model compartment of affected endothelial cells. The dynamics of the debris compartment
was compared with a semiquantitatively assessed histological score of the lung tissue. One has to
acknowledge here that debris is not coupled with any other compartment of our system, and
hence, was only considered to explain the data. Since we used the same model for debris than in
Smith et al., data could in principle be used to justify the equation.
Sensitivity analysis of model parameters showed that not all parameters could be identified
with high certainty. We expect that this issue could be improved by better data, especially close
meshed time series in the early phase of the infection which are still lacking. We plan to com-
plete our data base regarding this issue in the near future especially with respect to data from
the early phase of infection which is unsufficiently covered at the moment to address quick
immune responses. Identified parameter sets resulted in a good agreement of model prediction
and data. However, acknowledging the above mentioned issues, our parameter set is prelimi-
nary requiring validation by additional experiments.
There are several ways to improve and further extent our model: At first, new therapeutic
interventions such as other antibiotic drugs could be included. Complexity of the model could
be improved if other readouts of the experiments are available such as comprehensive dynam-
ics of relevant cytokines. Qualitatively the model could be refined by adding a systemic
response model. This is not considered so far and could be a reason why the fit of data of
untreated mice which might become septic is less optimal than that of treated mice which were
cured, probably not reaching septic states. Several models of systemic infection and extrapul-
monary organ involvement were proposed in the literature and could be combined with our
model in the longer perspective (for example [8, 25–28]). However, we believe that data base
must be improved first to construct such comprehensive models containing numerous
unknown parameters and mechanisms. Therefore, both, model equations and parameters
must be considered as preliminary.
We conclude that we established a biomathematical model of pneumonia explaining quali-
tative phenomena as well as quantitative time series data of infected mice with and without
antibiotic treatment. We aim at improving the model on the basis of additional mice experi-
ments currently performed considering early time points and novel therapeutic options. We
also aim at translating our mouse model to the human situation.
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